BCLI

AcronymDefinition
BCLIBritish Columbia Law Institute
BCLIBert Corona Leadership Institute (Washington, DC)
BCLIBluegrass Club of Long Island (New York)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
(103) In 2011, the British Columbia Law Institute (BCLI) published its report addressing the confusion over the continuing relevance of notice and recommending statutory amendments that retained the modified version of the doctrine of notice that exists in British Columbia.
For the BclI, N363S, Tth111I, and ER22/23EK GR polymorphisms DNA was extracted using the Phusion Blood Direct PCR Kit (New England Biolabs, UK), according to the manufacturer's instructions.
Para el diagnostico molecular indirecto prenatal y de portadoras, se utilizaron para HA, los polimorfismos BclI, (CA)n y (GT)n (AG)n; su nivel de heterocigosis a nivel mundial ha sido reportado en 39,3% (16); 42% (13,17) y 46,3% (31).
We designed the multiplex I-PCR strategy for Inv22 genotyping, using human genomic DNA sequence files that span either a relevant part of or the entire BclI restriction fragment obtained by classic Southern blot analysis for Inv22 (21.5 and 20.0 kb).
The BclI site was suggested to be situated in either the first or second intron of the GR gene (6).
(NASDAQ: BCLI) will present two scientific posters as platform presentations at the American Academy of Neurology annual meeting, to take place April 21-27th in Los Angeles, California, the company said.
(NASDAQ: BCLI) announced that the Mellen Center for MS Treatment and Research at Cleveland Clinic will be the first U.S.
(BCLI) to initiate a Phase 2 clinical trial of NurOwn for the treatment of progressive multiple sclerosis (MS).
(NASDAQ: BCLI) has appointed Anthony Polverino, Ph.D., to its board of directors, the company said.
(BCLI) an additional patent titled "Methods of Generating Mesenchymal Stem Cells which Secrete Neurotrophic Factors."
(BCLI) said it has submitted an Investigational New Drug (IND) application with the FDA to begin a Phase 2 study of NurOwn in patients with progressive multiple sclerosis (MS).
(BCLI) announced that an independent Data Safety Monitoring Board (DSMB) has found no significant safety concerns and recommended that the Phase 3 trial of the therapy known as NurOwn in ALS (NCT03280056) continue.